FMR LLC lowered its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 2.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,184,158 shares of the biopharmaceutical company's stock after selling 31,419 shares during the quarter. FMR LLC owned 0.76% of TG Therapeutics worth $27,697,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its holdings in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 849 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in shares of TG Therapeutics during the second quarter worth about $35,000. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics during the third quarter worth about $53,000. Finally, Values First Advisors Inc. acquired a new position in shares of TG Therapeutics during the third quarter worth about $58,000. Institutional investors and hedge funds own 58.58% of the company's stock.
TG Therapeutics Stock Down 3.6 %
Shares of NASDAQ TGTX traded down $1.17 during midday trading on Tuesday, reaching $31.67. 2,638,407 shares of the company's stock were exchanged, compared to its average volume of 3,626,240. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The stock has a market capitalization of $4.93 billion, a PE ratio of -328.37 and a beta of 2.25. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The business's fifty day moving average price is $27.83 and its two-hundred day moving average price is $23.03.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.73 earnings per share. Analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current year.
Insider Activity at TG Therapeutics
In related news, Director Sagar Lonial sold 5,000 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of brokerages have commented on TGTX. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 price objective on the stock. HC Wainwright boosted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.67.
Read Our Latest Research Report on TGTX
TG Therapeutics Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
